Novavax has been on a roll with its RSV (respiratory syncytial virus) vaccine lately, landing an $89 million Gates Foundation grant, reporting promising Phase II results in infants and launching a Phase III trial in older adults. Now, the Gaithersburg, MD-based biotech is starting a second Phase III trial in pregnant women to gauge the vaccine's efficacy in infants through maternal immunization.
Barely a month after reporting promising Phase II results for its respiratory syncytial virus (RSV) jab and netting an $89 million Gates Foundation grant, Gaithersburg, MD-based Novavax is going full steam ahead, initiating a Phase III trial for its RSV candidate.
Things are heating up in the race for a respiratory syncytial virus (RSV) vaccine.Novavax reported Phase II results for its investigational vaccine just a week ago, and now, Danish biotech Bavarian Nordic is starting a Phase I trial of its candidate.
There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.
Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus to market--and one just picked up a regulatory boost.
The partnership sees Astellas team up with ClearPath, a Maryland-based company that helps develop early-stage drugs.
Taiwanese researchers are developing a virus-based RSV vaccine that could complete preclinical studies next year, and has already shown signs of efficacy.
A team at the University of Saskatchewan, along with VIDO-InterVac, is developing a nasal vaccine against respiratory syncytial virus that shows promise in the lab.
Ann Arbor, MI-based NanoBio Corporation said it's teaming up with an unnamed Merck subsidiary on preclinical development of an intranasal vaccine for Respiratory Syncytial Virus (RSV)....
Researchers have finally figured out why a respiratory syncytial virus vaccine used in 1966 to innoculate children against the infection failed and caused severe respiratory disease. The team, led by